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J.B. Collip and the Development of Medical Research in Canada: 
Extracts and Enterprise. By Alison Li. (Montréal: McGill-Queen's 
University Press, 2003. xiv + 244 p., ill., notes, bibl, index. ISBN 0-
7735-2609-9 $39.95) 
Most people are probably unfamiliar with the name James Bertram 
Collip (1892-1965), often dubbed "the forgotten member of the insulin 
team." The discovery of insulin in 1921-1922 put the University of 
Toronto on the medical research map and immortalized the names 
Frederick Banting and Charles Best, and to a much lesser degree John 
James Rickard Macleod and J.B. Collip. (Cf Michael Bliss, The 
Discovery of Insulin, Toronto: McClelland and Stewart, 1988; 
"J.B.Collip: A Forgotten Member of the Insulin Team," in Essays in the 
History of Canadian Medicine, edited by Wendy Mitchinson and Janice 
Dicken McGinnis, Toronto: McClelland and Stewart, 1988.) It was a 
turning point in the lives of the four insulin team members, including 
Collip, whose scientific career developed in extraordinary ways 
thereafter. In this biography of Collip's life and career, Alison Li 
demonstrates how Collip as a "scientist" and an "entrepreneur of science" 
contributed to the evolving structure, conduct and fimding of medical 
research in Canada beyond the insulin discovery (p. xii). 
Like all good biographies, this study presents a narrative of a life as 
well as the context within which it was lived. Li describes CoUip's 
talents, drive, setbacks and achievements while also providing insight 
into medical research structures, the nature of scientific collaborations, 
the rise of endocrinology as a profession, the role of the pharmaceutical 
industry and the commercialization of medical products, among other 
themes. The first chapter outlines CoUip's formative beginnings against 
the background of provincial education and scientific research of the 
times: his birth and early childhood in Belleville, Ontario; his entry at the 
age of 15 into the science program at Trinity College; his graduate 
training in biochemistry under mentor Archibald Byron Macallum at the 
University of Toronto; and his first academic job at the newly established 
University of Alberta. The second chapter describes CoUip's sabbatical 
leave at the University of Toronto and his role in the discovery of insulin, 
specifically his contribution of purifying insulin and identifying its 
physiological effects. As the impact of the discovery became evident, Li 
recounts the internal frictions among the members of the insulin team as 
well as CoUip's shrewd long-distance negotiations with University of 
Alberta administrators to improve the terms of his position. 
After insulin, CoUip's next scientific accomplishment was the 
preparation of an active extract of the parathyroid hormone. Chapter three 
describes this achievement and, most welcome, is Li's analysis of the 
priority dispute, patent claims and industrial competition that fueled 
controversy over this work. Between 1924 and 1927, Collip conducted 
experiments on the parathyroid hormone and established his authority on 
the subject, apparently unaware of similar results completed earlier by 
medical practitioner Adolph Hanson. The controversy took on the 
dimensions of the "career scientist" (Collip) versus the "lone physician-
scientist" (Hanson) (p. 45). Eli Lilly & Company developed CoUip's 
parathyroid extract while Parke-Davis & Company marketed Hanson's 
parathyroid extract, with each firm offering competing unit sizes for the 
hormone—"Collip Units" and "Hanson Units" respectively (p. 51). In 
1932, Hanson won his patent claim for his clinical results; however the 
scientific community credited the discovery to Collip for his 
experimental science results relating to the extract preparation and its 
physiological actions. The case demonstrated that, while collaborative 
ventures between academic and commercial laboratories translated into 
quicker practical application and generated new funds for research in the 
form of royalties, it did not come without a price. Li argues that "the 
technicalities of patent law and the demands of commerce reshaped the 
manner in which scientific findings were transmitted and the priority for 
discoveries was established" (p. 58). 
In 1928, Collip left the University of Alberta to become Chair of the 
Department of Biochemistry at McGill University, where he remained 
until 1947. For these two decades, Collip was on top of his game. 
Chapters four, five and six focus on "the great years" of Collip's research 
career, predominantly his scientific work on the isolation and study of 
specific sex hormones, his management of a large, productive laboratory, 
and his skill at sustaining his broad research program financially. 
Working with the hormones of the placenta, Collip isolated Emmenin, the 
first orally active estrogen in the early 1930s. Once again, Collip turned 
to Eli Lilly & Company to manufacture and distribute the hormone in the 
United States. For Canadian production, Collip worked with Ayerst, 
McKenna & Harrison, a small Montreal-based pharmaceutical company. 
Ayerst researchers later developed a more potent estrogen hormone, 
Premarin, which furthered their success in the field of estrogen 
replacement therapy. This in turn resulted in royalties paid to Collip, 
financially stabilizing his research program. Li points out that Collip 
successfully transitioned "from working with one or two associates to 
heading up a large laboratory group, a configuration that was to become 
characteristic of modern medical research" (p. 89). Not all clinician-
researchers or scientists of this period were able to do so. Collip fostered 
a cooperative and team environment in which researchers were awarded 
significant autonomy to pursue related endocrine research. A "hub of 
activity" during the 1930s, Collip's lab was incredibly productive in large 
part due to its combination of skilled researchers, including the 
histologist and anatomist Hans Seyle. According to Li, several factors 
contributed to the eventual breakdown of Collip's lab and its productivity 
by the end of the decade: Selye's departure in 1938; Collip's involvement 
in wartime administrative work relating to medical research; and new 
methods, techniques and instruments in protein chemistry that differed 
greatly from "Collip's intuitive, 'bathtub' style of chemistry" (p. 112). 
The role of the state in funding medical research in Canada after 
1938 is the focus of chapter 7, a chapter that stands on its own for anyone 
wanting a succinct account. {Cf. Alison Li, "Expansion and 
Consolidation: The Associate Committee and the Division of Medical 
Research of the NRC, 1938-1959," in Building Canadian, edited by 
Richard A. Jarrell and Yves Gingras, special edition of Scientia 
Canadensis, 15, 1991.) Before 1938, medical research was funded 
predominantly by universities, philanthropists and pharmaceutical 
companies. Collip's research funds derived from a combination of public 
and private sources, including foundation grants, private donations, and 
royalties from insulin, Emmemin and Premarin. For most of his career, he 
had been well funded but he had not forgotten his early financial 
struggles at the University of Alberta. Not surprisingly, Collip supported 
increased public funding alongside private funding of research. Collip 
became a member of the Associate Committee on Medical Research soon 
after its formation in 1938, and later became chair upon Banting's 
untimely death in 1941, working to increase public funding and 
coordination of medical research in Canada. With Collip playing a 
contributing role, the outcome was an extramural system of funding 
which supported investigations carried out in existing university 
facilities. Comparatively, Britain and the United States supported mixed 
extramural and intramural systems. These governments provided funds 
for research at medical schools and universities as well as creating central 
laboratories at the National Institute for Medical Research at Mill Hill 
and the National Institutes of Health in Bethesda, Maryland respectively. 
Li argues that Canada's National Research Council did not have much 
choice but to support an extramural program in Canada because of 
financial constraints and the availability of personnel. There was not a 
critical mass of researchers and they were widely dispersed, as described 
by Banting in his 1939 survey of Canadian research centres. Nevertheless 
Canada's extramural system of medical research support worked, as 
stated by Li, assisting in the "growth of medical research" and shaping 
"its institutions in the postwar period" (p. 165). 
In chapters 6 and 7 which focus on medical research funding, perhaps 
Li might have expanded on several points. What was the role of 
philanthropic funding in medical research in Canada comparative to the 
United States and Great Britain? As Li mentions, the Bronfmans agreed 
to fund additional laboratories at McGill (p. 139-140); but with private 
philanthropists may come confrontation, such as the case of Thomas 
Bassett Macaulay (p. 72-76). What role did agencies, foundations and/or 
individuals play in shaping the type of medical research conducted? Is 
this not evident with disease-specific funding programs targeting 
tuberculosis, cancer, arthritis and rheumatism which may also reflect 
basic research verses clinical study funding debates? (p. 161-162) 
Lastly, and clearly indicating my own interest, I found the final chapter 
on Collip's appointment as Dean of Medicine (1947-1961) and Professor 
of Medical Research (1947-1965) at the University of Western Ontario 
thin. I wanted to know more about his impact on medical education and 
research. Surely Collip's eighteen-year tenure at this university warranted 
more than five pages. Still standing today is the building with the 
inscription "Collip Medical Research Laboratory" which was so named 
after the addition of a storey and wing to the existing structure to 
accommodate the arrival of Collip and his staff. Collip died in 1965, and 
two years later the Department of Medical Research was disbanded. 
Quibbles aside, this biography of Collip is well written, exhaustively 
researched, and rich in context. Li offers insight into the strengths and 
weaknesses of this man who as a scientist, entrepreneur, and leader 
contributed to key developments in the field of endocrinology and the 
institutionalization of medical research in Canada. Li reminds us that 
many of Collip's funding issues remain for today's researchers. Perhaps 
the difference being that today's medical research controversies are much 
more public with greater suspicions surrounding pharmaceutical 
company funded research. Anyone interested in the historical changes of 
twentieth-century medical research should read this book. 
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